INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease Publication INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…CertaraJanuary 8, 2025
Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development Video Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…CertaraDecember 10, 2024
Impactful Real World Evidence Solutions Brochure Impactful Real World Evidence Solutions CertaraOctober 9, 2024
Using Real World Data in Clinical Trial Submissions Blog Using Real World Data in Clinical Trial Submissions We explore challenges & best practice recommendations to help you implement submission standards when using…CertaraJune 17, 2024
Using Real World Evidence to Inform Treatment Guidelines Case Study Using Real World Evidence to Inform Treatment Guidelines Real-World Evidence (RWE) has become increasingly valuable in informing the development of treatment guidelines for…CertaraApril 5, 2023
Using Real-world Evidence to Advance Market Access for New Therapeutics White Paper Using Real-world Evidence to Advance Market Access for New Therapeutics CertaraSeptember 29, 2021
The Scary Future of Rare Disease Management On-Demand Webinar The Scary Future of Rare Disease Management In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…CertaraSeptember 23, 2021
Three Pathways have emerged in Innovative Access Agreements On-Demand Webinar Three Pathways have emerged in Innovative Access Agreements The days of simply determining the market demand for a new drug as a function…CertaraJune 11, 2021
Outcomes Based Agreements On-Demand Webinar Outcomes Based Agreements The days of simply determining the market demand for a new drug as a function…CertaraJune 11, 2021
Stakeholder perspectives: current and potential benefits On-Demand Webinar Stakeholder perspectives: current and potential benefits Amongst the real world data sources in Europe, the French Healthcare database SNDS is the…CertaraMay 26, 2021